Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Substance misuse is one of the most pervasive challenges around the globe, keeping this it in mind, company has announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse disorder.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Brandon Kerzner
Deal Size : $2.1 million
Deal Type : Private Placement
Details : Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Product Name : PEX010
Product Type : Controlled Substance
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Brandon Kerzner
Deal Size : $2.1 million
Deal Type : Private Placement
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
Details : Research shows that up to 80 percent of patients with advanced cancer for Psilocybin are likely to suffer distressing thoughts around death and up to 50 percent of patients with generally incurable conditions are likely to have psychiatric diagnoses.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Hebrew University Of Jerusalem
Deal Size : Undisclosed
Deal Type : Partnership
Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University
Details : Clearmind Medicine signed agreement to fund research and development projects with the Hebrew University of Jerusalem, Israel, focused on developing novel and patentable psychedelic molecules in search of potential drug candidates for the treatment of me...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Hebrew University Of Jerusalem
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : SABI Mind
Deal Size : Undisclosed
Deal Type : Agreement
Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
Details : The Company has signed an agreement which will provide SABI Mind’s trained clinical staff with supplies of GMP psilocybin and 3,4-Methylenedioxymethamphetamine (“MDMA”), pending the anticipated approval of its previously announced licensing amendme...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : SABI Mind
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Psyence Taps Another Pharma Exec to Drive its Clinical Program
Details : Psyence is designing market-leading clinical trials using natural psilocybin in the field of palliative care, which will initially be conducted in the United Kingdom.
Product Name : PEX010
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific's team of researchers also continue to carry out multiple psychedelic-based clinical research trials.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ketamine has been almost exclusively studied as an antidepressant adjunct to other antidepressants. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Pure Extracts Technologies
Deal Size : Undisclosed
Deal Type : Partnership
Details : Company announce development of nature-derived psilocybin extracts and advanced psilocybin formulations for the long-term treatment of psychological trauma and its mental health consequences.
Product Name : PEX010
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 28, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Pure Extracts Technologies
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Johns Hopkins University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This agreement allows Johns Hopkins University and Mydecine to further collaborate to advance research, on novel psychedelic therapies to treat mental health and addiction disorders.
Product Name : MYCO-001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 18, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Johns Hopkins University
Deal Size : Undisclosed
Deal Type : Collaboration